The text starts here.

Non-Consolidated Semiannual Financial Report for fiscal 1997

MAJOR R&D PIPELINE CANDIDATES (JAPAN)

1. APPROVED IN JAPAN

Brand (Code)

Description

Approval Form Origin
PARIET (E3810) Peptic Ulcer Treatment Oct-97 Tab. In-house

2. FILED FOR APPROVAL IN JAPAN

Code

Target Disease/Classification

Filing Form Origin
E6010 Myocardial Infarction/Second Generation t-PA Aug-94 Inj. In-house
E5510 Thrombosis/Anti-thrombotic, Anti-platelet Dec-95 Tab. In-house
E1077 Infection/Fourth Generation Cephalosporin Mar-97 Inj. In-house

3. PHASE III PRODUCTS IN JAPAN

Code

Target Disease/Classification

Filing (Est) Form Origin
E2020 Alzheimer's Disease/Reversible Acetylcholinesterase Inhibitor 1999 Tab. In-house
E7155 MRI Contrast Medium 1998 Inj. Bracco

4. PHASE II PRODUCTS IN JAPAN

Code

Target Disease/Classification

Form Origin
E5880 Shock, DIC/PAF Receptor Antagonist Inj. In-house
E6123 Asthma/PAF Receptor Antagonist Tab. In-house
E1101 Infection/Oral Cephalosporin Tab. In-house
E3330 Hepatic Failure/TNF Synthesis Inhibitor Tab. In-house
E3620 Functional Dyspepsia, Irritable Bowel Syndrome, Chemo-therapy Induced Emesis/5-HT3 Receptor Antagonist, 5-HT4 Receptor Agonist Tab./Inj. In-house
E3040 Inflammatory Bowel Disease/Multimediator Inhibitor Tab. In-house
E6700 Asthma/LTs-TXA2 Synthetase Inhibitor Tab. In-house